Aztreonam interactions
Aztreonam (Azactam, Cayston), an antibiotic has 46 documented interactions across the FDA labels and fact sheets we index: 0 major, 46 moderate, 0 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.
Interactions from the label
Moderate interactions (46)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam label, Warnings and precautions)
Check Aztreonam against everything you take. Add your full list; every pair is checked at once.
Open in the checkerNot medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.